Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130 that is in phase I clinical trial for the treatment of advanced solid tumors. Its preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25; TNFRSF25 modulators for various immunotherapy approaches; and COVID-19 vaccine. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
IPO Year:
Exchange: NASDAQ
Website: heatbio.com
Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it has completed the acquisition of Elusys Therapeutics, Inc. a commercial-stage biodefense company and developer of ANTHIM® (obiltoxaximab), a treatment for inhalation anthrax. ANTHIM® is approved for use in the U.S. and Canada, and under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. Nighthawk
DURHAM, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, today announced that it is changing the name of the Company to NightHawk Biosciences, Inc., effective May 3, 2022, to better reflect the Company's evolution, including expansion of its therapeutic pipeline, the vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company's new biodefense capabilities. In connection with the name change, the Company's ticker will change to "NHWK," effec
DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced CEO Jeff Wolf will host a conference call on Thursday, September 2nd at 11:00 A.M. Eastern Time to provide an update on the Company's activities. The conference call may be accessed by dialing 844-602-0380 for U.S. callers or +1 862-298-0970 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2768/42602 or on the Company's website at https://ir.heatbio.com/. An audio replay of the call will be available th
SC 13D/A - NightHawk Biosciences, Inc. (0001476963) (Subject)
SC 13D/A - HEAT BIOLOGICS, INC. (0001476963) (Subject)
4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)
4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)
4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)
4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)
4 - NightHawk Biosciences, Inc. (0001476963) (Issuer)
4 - HEAT BIOLOGICS, INC. (0001476963) (Issuer)
4 - HEAT BIOLOGICS, INC. (0001476963) (Issuer)
4 - HEAT BIOLOGICS, INC. (0001476963) (Issuer)
4 - HEAT BIOLOGICS, INC. (0001476963) (Issuer)
4 - HEAT BIOLOGICS, INC. (0001476963) (Issuer)
Cantor Fitzgerald initiated coverage of Heat Biologics with a rating of Overweight and set a new price target of $22.00
Cantor Fitzgerald initiated coverage of Heat Biologics with a rating of Overweight
Alliance Global Partners reiterated coverage of Heat Biologics with a rating of Buy and set a new price target of $40.00 from $5.00 previously
Maxim Group resumed coverage of Heat Biologics with a rating of Buy and set a new price target of $14.00
8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
10-Q - NightHawk Biosciences, Inc. (0001476963) (Filer)
8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
S-8 - NightHawk Biosciences, Inc. (0001476963) (Filer)
8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
10-Q - NightHawk Biosciences, Inc. (0001476963) (Filer)
8-K - NightHawk Biosciences, Inc. (0001476963) (Filer)
DEF 14A - NightHawk Biosciences, Inc. (0001476963) (Filer)
DURHAM, N.C., March 23, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, announces the appointment of Greg Burel, former Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR) Director of the Strategic National Stockpile (SNS), to the Company's Biothreat Advisory Board and as a senior advisor to the Company. Mr. Burel served as the Director of SNS from March 2007 to January 2020. In this role, Mr. Burel directed the nation's premier medical materiel prepared
DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the appointment of Paul Tebbey, Ph.D. as Senior Vice President of Product Development and Portfolio Strategy. Dr. Tebbey is a pharmaceutical development strategy leader with over 25 years of healthcare and management experience across the biotechnology and pharmaceutical sectors at companies such as Abbvie, Baxter, Centocor/Johnson & Johnson and Wyeth/Pfizer. Dr. Tebbey's research, development and commercial launch experiences include novel monoclonal antibodies
DURHAM, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced the appointment of Anthony Manning, Ph.D. as Chief Scientific Advisor. Dr. Manning will be responsible for strategic initiatives to accelerate the development of Heat Biologics' product portfolio. Dr. Manning brings over three decades of experience in immunology and autoimmune disease research and development. Most recently, Dr. Manning served as Chief Scientific Officer and Head of Research at M
DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Matthew Seavey, Ph.D., MBA, NightHawk's Vice President of Research will be presenting data on PTX-35, and serving on an expert panel discussing modes of Treg activation, at the 4th Annual Treg Directed Therapies Summit being held on May 17-19th in Boston. PTX-35 is a novel, potential first-in-class antibody immunomodulator of TNFRSF25 (death receptor 3), a receptor that is preferentially expressed by antigen-experienced T cells and can be utilized to expand regulator
DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that it has completed its name change from Heat Biologics, Inc. to NightHawk Biosciences, Inc. to better reflect the Company's evolution, including expansion of the therapeutic pipeline, vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company's new biodefense capabilities. In connection with the name change, the Company's ticker will change to "NHWK," effective today, May
DURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced to shareholders that its Elusys Therapeutics subsidiary has finalized a contract with the Canadian government to deliver ANTHIM® (obiltoxaximab for injection), a treatment for inhalation anthrax, for use against a potential anthrax attack. ANTHIM® will be delivered to Canada's National Emergency Strategic Stockpile under a procurement contract totaling CAD $7.9 millioni. The goal of this program is to establish a Canadian
Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it has completed the acquisition of Elusys Therapeutics, Inc. a commercial-stage biodefense company and developer of ANTHIM® (obiltoxaximab), a treatment for inhalation anthrax. ANTHIM® is approved for use in the U.S. and Canada, and under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. Nighthawk
DURHAM, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, today announced that it is changing the name of the Company to NightHawk Biosciences, Inc., effective May 3, 2022, to better reflect the Company's evolution, including expansion of its therapeutic pipeline, the vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company's new biodefense capabilities. In connection with the name change, the Company's ticker will change to "NHWK," effec
DURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, reminds investors that it will host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments. The event will be broadcast at: https://vimeo.com/event/2027558/fc6de52c31 About Heat Biologics, Inc.Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies and vaccines to modulate the immune system. Heat's gp96 platform is designed to activate
DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, today announced it plans to host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments. The event will be broadcast at: https://vimeo.com/event/2027558/fc6de52c31 About Heat Biologics, Inc.Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies and vaccines to modulate the immune system. Heat's gp96 platform is designed to activate imm
DURHAM, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, today unveiled enhanced allogeneic cell therapy manufacturing capabilities through its Scorpion Biological Services subsidiary. Jeff Wolf, Chief Executive Officer of Heat, commented, "We are excited to rollout our new 3-D allogeneic cell manufacturing capabilities to replace our current 2-D HS-110 manufacturing. This new process is designed to increase yield, improve operating efficiency, as well as provide both a rapid and scalable solution
DURHAM, N.C., March 23, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, announces the appointment of Greg Burel, former Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR) Director of the Strategic National Stockpile (SNS), to the Company's Biothreat Advisory Board and as a senior advisor to the Company. Mr. Burel served as the Director of SNS from March 2007 to January 2020. In this role, Mr. Burel directed the nation's premier medical materiel prepared
DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the year ended December 31, 2021. Jeff Wolf, Chief Executive Officer of Heat, commented, "2021 was a transformative year for Heat as we progress our strategic evolution to become a fully-integrated biopharmaceutical company. On the clinical front, we presented favorable survival data at The American Association of Cancer Research (AACR) of HS-110 in combination with checkpoint inhibitors for the treatment
Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced to shareholders that its Elusys Therapeutics subsidiary has finalized a contract with the Canadian government to deliver ANTHIM® (obiltoxaximab for injection), a treatment for inhalation anthrax, for use against a potential anthrax attack. ANTHIM® will be delivered to Canada's National Emergency Strategic Stockpile under a procurement contract totaling CAD $7.9 millioni. The goal of this program is to establish a Canadian supply of Anthim for use as a medical countermea
Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, today announced that it is changing the name of the Company to NightHawk Biosciences, Inc., effective May 3, 2022, to better reflect the Company's evolution, including expansion of its therapeutic pipeline, the vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company's new biodefense capabilities. In connection with the name change, the Company's ticker will change to "NHWK," effective May 3, 2022. The livestream event, held at the
Heat Biologics Inc (NYSE:HTBX) announced a planned development partnership of its Scorpion Biological Services subsidiary with a private developer, the State of Kansas, and local and university affiliates. The Company intends to utilize the new 500,000+ square foot facility for large molecule and biologics manufacturing, focusing on biodefense. In addition to servicing the Company's product pipeline, it plans to operate as a full-service Contract Development and Manufacturing Organization (CDMO) to provide third-party manufacturing services on a fee-for-service basis. Also Read: Heat Biologics Issues New PTX-35 Preclinical Data In Organ Transplantation, Update On HS-110. Once fully o
Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, today announced it plans to host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments. The event will be broadcast at: https://vimeo.com/event/2027558/fc6de52c31
https://ir.heatbio.com/press-releases/detail/706/heat-biologics-announces-planned-acquisition-of-elusys
Gainers JX Luxventure Limited (NASDAQ:LLL) shares jumped 119.5% to settle at $4.39 on Tuesday after the company announced it signed a $60 million sales agreement. Forge Global Holdings Inc. (NYSE:FRGE) shares climbed 59.7% to close at $16.15 on Tuesday. True Global Ventures’ portfolio company Forge Global Holdings completed its business combination with Motive Capital Corp on the 22nd of March, 2022. Q&K International Group Limited (NASDAQ:QK) gained 52.1% to settle at $2.19. Jupai Holdings Limited (NYSE:JP) jumped 48.3% to close at $0.71. Draganfly Inc. (NASDAQ:DPRO) rose 41.3% to settle at $2.36 after the company announced it received an order for its Medical Response and Search an
B. Riley Securities analyst Mayank Mamtani maintains Heat Biologics (AMEX:HTBX) with a Buy and lowers the price target from $10 to $8.
https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Reserach_03172022_HTBX_Vandermosten.pdf